Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN SODIUM CHLORIDE 0 45 versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN SODIUM CHLORIDE 0 45 versus MAGNESIUM SULFATE.
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, and to a lesser extent factors IXa, XIa, and XIIa, thereby inhibiting coagulation.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
5000 units IV bolus followed by continuous IV infusion at 1300 units/hour, adjusted based on aPTT.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (dose-dependent, prolonged at high doses); clinical context: half-life increases with dose (nonlinear pharmacokinetics), up to 2.5-3 hours with 25,000 units.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Primarily hepatic metabolism (partial, via desulfation and depolymerization) and reticuloendothelial system uptake; renal excretion of metabolites; <1% unchanged in urine.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte